508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study. (4th December 2021)

• Record Type: Journal Article
• Authors: Alattar, Rand A; Ahmed, Shiema A; Abdallah, Tasneem; Kazman, Rashid; Qadmour, Aseelah N; Ibrahim, Tawheeda; Alhariri, Bassem; Shaar, Shahd H; Bajwa, Abeer; Alimam, Abeir; Qazi, Rabia; Abid, Fatma Ben; Daghfal, Joanne; Eldeeb, Ali M; Shukri, Kinda; Elsayed, Ahmed; Rustom, Fatima; AlSamawi, Musaed S; Abdelmajid, Alaaeldin A; Basulto, Miguel; Cobian, Armando; Khattab, Mohammed Abu; Almaslamani, Muna; Khal, Abdullatif Al; Omrani, Ali S
• Is Part Of: Open forum infectious diseases. Volume 8(2021)Supplement 1
• Page Start: S356
• Page End: S356
• Publication Date: 2021-12-04
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab466.707
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Methods: Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. Cox regression was used to examine associations with the primary endpoint. Results: The unmatched cohort included 1, 493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline (table 1). Favipiravir was started within a median of 5 days from symptoms onset. Significant baseline differences between the two unmatched groups existed, but not between the PSmatched groups (N = 774) (table 1). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360) (Table 2). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001) (table 2). In the adjusted Cox proportional hazards model, favipiravir therapy was not associated 28-day clinical improvement (adjusted hazard ratio 0.978, 95% confidence interval 0.862 –1.109, P 0.726) (Table 3). Conclusion: Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days. Disclosures: All Authors : No reported disclosures